NASDAQ:RGLS

Regulus Therapeutics Competitors

$1.20
-0.09 (-6.98 %)
(As of 04/19/2021 10:51 AM ET)
Add
Compare
Today's Range
$1.19
Now: $1.20
$1.27
50-Day Range
$1.15
MA: $1.51
$1.96
52-Week Range
$0.42
Now: $1.20
$2.32
Volume27,600 shs
Average Volume2.98 million shs
Market Capitalization$87.01 million
P/E RatioN/A
Dividend YieldN/A
Beta2.41

Competitors

Regulus Therapeutics (NASDAQ:RGLS) Vs. AMGN, GILD, VRTX, REGN, BIIB, and ALXN

Should you be buying RGLS stock or one of its competitors? Companies in the sub-industry of "biotechnology" are considered alternatives and competitors to Regulus Therapeutics, including Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Alexion Pharmaceuticals (ALXN).

Amgen (NASDAQ:AMGN) and Regulus Therapeutics (NASDAQ:RGLS) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, earnings, dividends and risk.

Institutional & Insider Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 20.0% of Regulus Therapeutics shares are owned by institutional investors. 0.4% of Amgen shares are owned by insiders. Comparatively, 18.2% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Amgen and Regulus Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amgen$23.36 billion6.29$7.84 billion$14.8217.22
Regulus Therapeutics$6.83 million12.74$-18,590,000.00($1.08)-1.11

Amgen has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and price targets for Amgen and Regulus Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amgen091402.61
Regulus Therapeutics02102.33

Amgen currently has a consensus price target of $261.1429, indicating a potential upside of 2.44%. Regulus Therapeutics has a consensus price target of $1.25, indicating a potential upside of 4.17%. Given Regulus Therapeutics' higher probable upside, analysts plainly believe Regulus Therapeutics is more favorable than Amgen.

Profitability

This table compares Amgen and Regulus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amgen29.42%95.55%15.52%
Regulus TherapeuticsN/A-150.66%-57.52%

Volatility and Risk

Amgen has a beta of 0.76, indicating that its share price is 24% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500.

Summary

Amgen beats Regulus Therapeutics on 10 of the 14 factors compared between the two stocks.

Regulus Therapeutics (NASDAQ:RGLS) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Profitability

This table compares Regulus Therapeutics and Gilead Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regulus TherapeuticsN/A-150.66%-57.52%
Gilead Sciences5.48%37.77%12.76%

Analyst Ratings

This is a summary of current recommendations for Regulus Therapeutics and Gilead Sciences, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regulus Therapeutics02102.33
Gilead Sciences191302.52

Regulus Therapeutics currently has a consensus target price of $1.25, indicating a potential upside of 4.17%. Gilead Sciences has a consensus target price of $97.92, indicating a potential upside of 48.30%. Given Gilead Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Gilead Sciences is more favorable than Regulus Therapeutics.

Insider and Institutional Ownership

20.0% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are owned by institutional investors. 18.2% of Regulus Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Regulus Therapeutics has a beta of 2.41, indicating that its stock price is 141% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.

Earnings and Valuation

This table compares Regulus Therapeutics and Gilead Sciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regulus Therapeutics$6.83 million12.74$-18,590,000.00($1.08)-1.11
Gilead Sciences$22.45 billion3.69$5.39 billion$6.1410.73

Gilead Sciences has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Summary

Gilead Sciences beats Regulus Therapeutics on 11 of the 14 factors compared between the two stocks.

Vertex Pharmaceuticals (NASDAQ:VRTX) and Regulus Therapeutics (NASDAQ:RGLS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings for Vertex Pharmaceuticals and Regulus Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vertex Pharmaceuticals042112.88
Regulus Therapeutics02102.33

Vertex Pharmaceuticals currently has a consensus price target of $293.1250, indicating a potential upside of 31.85%. Regulus Therapeutics has a consensus price target of $1.25, indicating a potential upside of 4.17%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Vertex Pharmaceuticals is more favorable than Regulus Therapeutics.

Profitability

This table compares Vertex Pharmaceuticals and Regulus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vertex Pharmaceuticals38.51%28.55%20.68%
Regulus TherapeuticsN/A-150.66%-57.52%

Risk and Volatility

Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 2.41, suggesting that its stock price is 141% more volatile than the S&P 500.

Earnings & Valuation

This table compares Vertex Pharmaceuticals and Regulus Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vertex Pharmaceuticals$4.16 billion13.67$1.18 billion$4.2951.24
Regulus Therapeutics$6.83 million12.74$-18,590,000.00($1.08)-1.11

Vertex Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

92.2% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.0% of Regulus Therapeutics shares are owned by institutional investors. 0.7% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Vertex Pharmaceuticals beats Regulus Therapeutics on 13 of the 15 factors compared between the two stocks.

Regeneron Pharmaceuticals (NASDAQ:REGN) and Regulus Therapeutics (NASDAQ:RGLS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, dividends, analyst recommendations and profitability.

Insider & Institutional Ownership

85.0% of Regeneron Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.0% of Regulus Therapeutics shares are owned by institutional investors. 11.8% of Regeneron Pharmaceuticals shares are owned by insiders. Comparatively, 18.2% of Regulus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Regeneron Pharmaceuticals and Regulus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regeneron Pharmaceuticals38.28%28.97%20.11%
Regulus TherapeuticsN/A-150.66%-57.52%

Analyst Ratings

This is a breakdown of current recommendations for Regeneron Pharmaceuticals and Regulus Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regeneron Pharmaceuticals051412.80
Regulus Therapeutics02102.33

Regeneron Pharmaceuticals presently has a consensus target price of $646.2609, indicating a potential upside of 28.02%. Regulus Therapeutics has a consensus target price of $1.25, indicating a potential upside of 4.17%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Regeneron Pharmaceuticals is more favorable than Regulus Therapeutics.

Earnings & Valuation

This table compares Regeneron Pharmaceuticals and Regulus Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regeneron Pharmaceuticals$7.86 billion6.85$2.12 billion$21.4723.41
Regulus Therapeutics$6.83 million12.74$-18,590,000.00($1.08)-1.11

Regeneron Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Regeneron Pharmaceuticals has a beta of 0.3, meaning that its stock price is 70% less volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 2.41, meaning that its stock price is 141% more volatile than the S&P 500.

Summary

Regeneron Pharmaceuticals beats Regulus Therapeutics on 12 of the 15 factors compared between the two stocks.

Regulus Therapeutics (NASDAQ:RGLS) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, valuation, institutional ownership, profitability, analyst recommendations and dividends.

Risk and Volatility

Regulus Therapeutics has a beta of 2.41, meaning that its share price is 141% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500.

Earnings and Valuation

This table compares Regulus Therapeutics and Biogen's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Regulus Therapeutics$6.83 million12.74$-18,590,000.00($1.08)-1.11
Biogen$14.38 billion2.83$5.89 billion$33.577.96

Biogen has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Regulus Therapeutics and Biogen's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Regulus TherapeuticsN/A-150.66%-57.52%
Biogen35.63%51.00%23.54%

Analyst Recommendations

This is a summary of current ratings for Regulus Therapeutics and Biogen, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Regulus Therapeutics02102.33
Biogen5141202.23

Regulus Therapeutics currently has a consensus target price of $1.25, suggesting a potential upside of 4.17%. Biogen has a consensus target price of $303.3103, suggesting a potential upside of 12.80%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Regulus Therapeutics.

Institutional and Insider Ownership

20.0% of Regulus Therapeutics shares are owned by institutional investors. Comparatively, 83.5% of Biogen shares are owned by institutional investors. 18.2% of Regulus Therapeutics shares are owned by insiders. Comparatively, 0.5% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Biogen beats Regulus Therapeutics on 10 of the 14 factors compared between the two stocks.

Alexion Pharmaceuticals (NASDAQ:ALXN) and Regulus Therapeutics (NASDAQ:RGLS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership and dividends.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500. Comparatively, Regulus Therapeutics has a beta of 2.41, indicating that its share price is 141% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Alexion Pharmaceuticals and Regulus Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alexion Pharmaceuticals017412.27
Regulus Therapeutics02102.33

Alexion Pharmaceuticals currently has a consensus price target of $153.4286, suggesting a potential downside of 7.19%. Regulus Therapeutics has a consensus price target of $1.25, suggesting a potential upside of 4.17%. Given Regulus Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Regulus Therapeutics is more favorable than Alexion Pharmaceuticals.

Institutional and Insider Ownership

87.3% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.0% of Regulus Therapeutics shares are owned by institutional investors. 4.0% of Alexion Pharmaceuticals shares are owned by company insiders. Comparatively, 18.2% of Regulus Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Alexion Pharmaceuticals and Regulus Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alexion Pharmaceuticals$4.99 billion7.33$2.40 billion$9.7417.01
Regulus Therapeutics$6.83 million12.74$-18,590,000.00($1.08)-1.11

Alexion Pharmaceuticals has higher revenue and earnings than Regulus Therapeutics. Regulus Therapeutics is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Alexion Pharmaceuticals and Regulus Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alexion Pharmaceuticals16.32%23.16%14.76%
Regulus TherapeuticsN/A-150.66%-57.52%

Summary

Alexion Pharmaceuticals beats Regulus Therapeutics on 10 of the 15 factors compared between the two stocks.


Regulus Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Amgen logo
AMGN
Amgen
2.3$255.24-0.2%$147.24 billion$23.36 billion20.58Analyst Report
Analyst Revision
Gilead Sciences logo
GILD
Gilead Sciences
2.8$65.88-1.5%$84.19 billion$22.45 billion67.92Analyst Revision
Vertex Pharmaceuticals logo
VRTX
Vertex Pharmaceuticals
2.2$219.80-0.2%$56.78 billion$4.16 billion27.75Analyst Revision
Regeneron Pharmaceuticals logo
REGN
Regeneron Pharmaceuticals
2.6$502.66-0.0%$53.84 billion$7.86 billion18.37
Biogen logo
BIIB
Biogen
1.9$267.35-1.1%$41.18 billion$14.38 billion8.85Upcoming Earnings
Analyst Report
Analyst Revision
Alexion Pharmaceuticals logo
ALXN
Alexion Pharmaceuticals
1.7$165.66-1.2%$36.16 billion$4.99 billion38.71
Seagen logo
SGEN
Seagen
1.7$143.95-1.1%$26.38 billion$916.71 million56.67Increase in Short Interest
Exact Sciences logo
EXAS
Exact Sciences
1.8$125.53-3.6%$21.99 billion$876.29 million-56.80
Incyte logo
INCY
Incyte
1.7$82.01-0.8%$18.18 billion$2.16 billion-52.24
Novavax logo
NVAX
Novavax
1.2$216.40-5.1%$16.79 billion$18.66 million-41.46
Alnylam Pharmaceuticals logo
ALNY
Alnylam Pharmaceuticals
1.8$138.61-0.2%$16.29 billion$219.75 million-17.70
BioMarin Pharmaceutical logo
BMRN
BioMarin Pharmaceutical
1.9$79.18-0.3%$14.44 billion$1.70 billion18.12Analyst Report
Repligen logo
RGEN
Repligen
1.5$209.42-1.9%$11.68 billion$270.24 million255.39Analyst Report
Neurocrine Biosciences logo
NBIX
Neurocrine Biosciences
2.3$94.56-2.1%$9.13 billion$788.10 million101.68Analyst Report
Increase in Short Interest
Analyst Revision
United Therapeutics logo
UTHR
United Therapeutics
1.5$201.35-1.2%$9.07 billion$1.45 billion19.05
Exelixis logo
EXEL
Exelixis
1.9$23.75-0.7%$7.36 billion$967.78 million49.48
Halozyme Therapeutics logo
HALO
Halozyme Therapeutics
1.5$46.68-0.6%$6.65 billion$195.99 million291.75
Ionis Pharmaceuticals logo
IONS
Ionis Pharmaceuticals
1.6$39.84-2.4%$5.74 billion$1.12 billion83.00Analyst Revision
Emergent BioSolutions logo
EBS
Emergent BioSolutions
2.0$70.55-10.0%$4.16 billion$1.11 billion22.68
Arena Pharmaceuticals logo
ARNA
Arena Pharmaceuticals
1.7$64.95-1.5%$3.98 billion$806.43 million-9.20Analyst Report
News Coverage
ChemoCentryx logo
CCXI
ChemoCentryx
1.6$45.43-2.4%$3.25 billion$36.13 million-67.81
Alkermes logo
ALKS
Alkermes
1.2$19.93-0.3%$3.16 billion$1.17 billion-43.33Insider Selling
OPKO Health logo
OPK
OPKO Health
1.9$4.16-4.3%$2.91 billion$901.90 million-23.11
Amicus Therapeutics logo
FOLD
Amicus Therapeutics
1.6$9.82-1.2%$2.63 billion$182.24 million-8.54Analyst Upgrade
News Coverage
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.6$146.37-2.6%$2.50 billion$120.28 million-147.85Unusual Options Activity
Myriad Genetics logo
MYGN
Myriad Genetics
1.0$26.63-2.6%$2.05 billion$638.60 million-10.24
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.7$121.34-2.8%$2.00 billionN/A-10.96
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.5$11.16-0.7%$2.00 billion$48.83 million-14.68
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.47-1.3%$1.71 billion$428.41 million15.17
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.15-3.0%$1.65 billion$102.43 million-18.58Analyst Upgrade
Codexis logo
CDXS
Codexis
1.3$22.80-3.5%$1.52 billion$68.46 million-65.14Analyst Report
News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.22-4.2%$1.50 billion$82.27 million-17.61
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$11.28-2.6%$1.24 billion$35.22 million-8.23
Innoviva logo
INVA
Innoviva
1.4$11.66-2.1%$1.21 billion$261.02 million5.95
Curis logo
CRIS
Curis
1.3$10.63-8.1%$1.05 billion$10 million-12.96Gap Up
MannKind logo
MNKD
MannKind
1.4$4.12-1.5%$1.04 billion$63.04 million-19.62Increase in Short Interest
Celldex Therapeutics logo
CLDX
Celldex Therapeutics
1.8$24.00-1.9%$932.93 million$3.57 million-10.76
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.38-1.8%$914.90 million$227.19 million45.50
Bolt Biotherapeutics logo
BOLT
Bolt Biotherapeutics
1.6$22.47-0.5%$812.29 millionN/A0.00
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.88-3.5%$728.99 million$322.07 million-4.65Upcoming Earnings
Decrease in Short Interest
News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.24-2.8%$716.63 million$150,000.00-4.63News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.16-0.6%$669.56 million$252 million-2.06
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.85-2.2%$625.09 million$143.01 million-1.12
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$3.43-4.4%$609.03 million$59.29 million-22.87Increase in Short Interest
News Coverage
Agenus logo
AGEN
Agenus
1.6$2.57-1.9%$536.28 million$150.05 million-2.36
Geron logo
GERN
Geron
1.4$1.39-5.8%$468.24 million$460,000.00-3.97Decrease in Short Interest
Gap Up
Spectrum Pharmaceuticals logo
SPPI
Spectrum Pharmaceuticals
1.5$2.89-3.8%$461.18 million$109.33 million-2.12
Verastem logo
VSTM
Verastem
1.3$2.70-0.7%$460.07 million$17.46 million-1.91
Molecular Templates logo
MTEM
Molecular Templates
2.0$7.82-3.8%$455.14 million$22.27 million-3.83Analyst Revision
XOMA logo
XOMA
XOMA
1.5$35.97-4.3%$422.18 million$18.37 million-32.41Increase in Short Interest
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.